Efficacy of somatostatine analogues in survival and quality of life of a frail patient with poorly differentiated biliary neuroendocrine tumour

Marco Alì, Antonino D’Agostino, Alfio Todaro, Andrea Girlando, Marcello Ferrara, Rosanna Aiello

DOI: https://doi.org/10.7175/cmi.v4i1S.1065


We describe the case of a 71-year-old woman with poorly differentiated neuroendocrine tumor of third distal biliary duct and osteolytic metastasis. The patient was evaluated as a third stage of Balducci’s criteria for the recognition of frailty. The patient received radiotherapy and octreotide LAR. This treatment allowed a good tumour progression rate (18 months), a good quality of life and a good survival (35 months). The case report describes the role of octreotide in the therapy of neuroendocrine tumours, and underlines the importance of a multidisciplinary management of cancer in frail patients.


Neuroendocrine tumours; Chromogranin A; Octreotide LAR; Frailty

Full Text



Abstract: 536 views
PDF: 630 views


  • There are currently no refbacks.